Search Results

You are looking at 91 - 100 of 106 items for :

  • "Bladder cancer" x
  • All content x
Clear All
Full access

David Cella, Sarah K. Rosenbloom, Jennifer L. Beaumont, Susan E. Yount, Diane Paul, Debra Hampton, Amy P. Abernethy, Paul B. Jacobsen, Karen Syrjala, and Jamie H. Von Roenn

other primary malignancy diagnosed or treated within the previous 5 years, excluding nonmelanoma skin cancer. A total of 533 patients participated in the study, with approximately 50 patients per disease site except for bladder cancer (n = 31). Table 1

Full access

NCCN Guidelines Insights: Survivorship, Version 2.2020

Featured Updates to the NCCN Guidelines

Crystal S. Denlinger, Tara Sanft, Javid J. Moslehi, Linda Overholser, Saro Armenian, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C. F. Moore, Natalie Moryl, Tracey O’Connor, Electra D. Paskett, Chirayu Patel, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

30% in survivors of small cell lung cancer. 51 Another study of >2 million cancer survivors in the SEER database identified bladder cancer survivors as having the highest risk for subsequent primary cancers (34% at 20 years). 52 Overall, this study

Full access

Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang

. Powles T , Eder JP , Fine GD , . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer . Nature 2014 ; 515 : 558 – 562 . https://doi.org/10.1038/nature13904PubMed 25428503 10.1038/nature13904 13. Robert C

Full access

Dominik J. Ose, Richard Viskochil, Andreana N. Holowatyj, Mikaela Larson, Dalton Wilson, William A. Dunson Jr, Vikrant G. Deshmukh, J. Ryan Butcher, Belinda R. Taylor, Kim Svoboda, Jennifer Leiser, Benjamin Tingey, Benjamin Haaland, David W. Wetter, Simon J. Fisher, Mia Hashibe, and Cornelia M. Ulrich

treatment markedly raises blood sugar levels and increases the risk for development of preDM. Regarding specific cancer types, we observed a high prevalence of DM in patients with pancreatic cancer, bladder cancer, and cancers of the respiratory system

Full access

Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang

. Powles T , Eder JP , Fine GD , et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer . Nature 2014 ; 515 : 558 – 562 . 13. Robert C , Thomas L , Bondarenko I , et al. Ipilimumab plus

Full access

Kerry Schaffer, Narmadha Panneerselvam, Kah Poh Loh, Rachel Herrmann, Ian R. Kleckner, Richard Francis Dunne, Po-Ju Lin, Charles E. Heckler, Nicholas Gerbino, Lauren B. Bruckner, Eugene Storozynsky, Bonnie Ky, Andrea Baran, Supriya Gupta Mohile, Karen Michelle Mustian, and Chunkit Fung

. Exercise programming and counseling preferences in bladder cancer survivors: a population-based study . J Cancer Surviv 2007 ; 1 : 27 – 34 . 57. Cobiac LJ Vos T Barendregt JJ . Cost-effectiveness of interventions to promote physical activity

Full access

Josh Lauring, Ben Ho Park, and Antonio C. Wolff

activating PIK3CA mutations, 54 , 55 whereas other studies have found no correlation between mutation and response, although most of these studies are underpowered. 56 Recently, mutation of the TSC1 and TSC2 genes in bladder cancers was found to correlate

Full access

Al B. Benson III, Thomas A. Abrams, Edgar Ben-Josef, P. Mark Bloomston, Jean F. Botha, Bryan M. Clary, Anne Covey, Steven A. Curley, Michael I. D'Angelica, Rene Davila, William D. Ensminger, John F. Gibbs, Daniel Laheru, Mokenge P. Malafa, Jorge Marrero, Steven G. Meranze, Sean J. Mulvihill, James O. Park, James A. Posey, Jasgit Sachdev, Riad Salem, Elin R. Sigurdson, Constantinos Sofocleous, Jean-Nicolas Vauthey, Alan P. Venook, Laura Williams Goff, Yun Yen, and Andrew X. Zhu

-naive, unresectable gall bladder cancer . Br J Cancer 2004 ; 90 : 1516 – 1520 . 210 Thongprasert S Napapan S Charoentum C Moonprakan S . Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma . Ann

Full access

Dawn Provenzale, Samir Gupta, Dennis J. Ahnen, Travis Bray, Jamie A. Cannon, Gregory Cooper, Donald S. David, Dayna S. Early, Deborah Erwin, James M. Ford, Francis M. Giardiello, William Grady, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, Scott E. Regenbogen, Niloy Jewel Samadder, Moshe Shike, Gideon Steinbach, David Weinberg, Mary Dwyer, and Susan Darlow

. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer . Eur Urol 2013 ; 63 : 379 – 385 . 77. Win AK Lindor NM Jenkins MA . Risk of breast cancer in

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian, and Maoko Naganuma

incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer . Cancer 2010 ; 116 : 2596 – 2603 . 36. Levitan N Dowlati A Remick SC . Rates of initial and recurrent thromboembolic disease among